See more : Tibet Mineral Development Co., LTD (000762.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of MedMen Enterprises Inc. (MMNFF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MedMen Enterprises Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Regal Corporation (7938.T) Income Statement Analysis – Financial Results
- Endurance Acquisition Corp. (EDNC) Income Statement Analysis – Financial Results
- GoGreen Investments Corporation (GOGN-UN) Income Statement Analysis – Financial Results
- Relic Technologies Limited (RELICTEC.BO) Income Statement Analysis – Financial Results
- Computer Age Management Services Limited (CAMS.NS) Income Statement Analysis – Financial Results
MedMen Enterprises Inc. (MMNFF)
About MedMen Enterprises Inc.
MedMen Enterprises Inc., together with its subsidiaries, operates as a cannabis company in the United States. The company cultivates, produces, distributes, and retails recreational and medicinal cannabis under the MedMen Red and LuxLyte brand names. As of December 25, 2021, it operated 29 stores in California, Florida, Nevada, Illinois, Arizona, Massachusetts, and New York. MedMen Enterprises Inc. is headquartered in Culver City, California.
Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 140.81M | 145.07M | 157.11M | 129.96M | 39.78M | 2.67M | 20.07K | 26.65K | 20.64K | 24.92K | 19.66K | 27.66K | 18.14K | 33.60K | 36.42K | 22.18K | 20.28K | 19.34K | 30.11K | 0.00 | 305.46K |
Cost of Revenue | 71.08M | 77.78M | 98.99M | 69.09M | 25.93M | 1.80M | 7.89K | 7.66K | 7.96K | 7.78K | 9.02K | 10.70K | 9.33K | 10.32K | 9.36K | 10.82K | 8.19K | 7.78K | 19.30K | 0.00 | 395.02K |
Gross Profit | 69.73M | 67.29M | 58.12M | 60.88M | 13.85M | 868.14K | 12.18K | 19.00K | 12.69K | 17.14K | 10.63K | 16.96K | 8.81K | 23.28K | 27.06K | 11.36K | 12.08K | 11.56K | 10.81K | 0.00 | -89.56K |
Gross Profit Ratio | 49.52% | 46.39% | 36.99% | 46.84% | 34.81% | 32.49% | 60.69% | 71.27% | 61.46% | 68.78% | 54.09% | 61.32% | 48.56% | 69.30% | 74.31% | 51.23% | 59.59% | 59.76% | 35.90% | 0.00% | -29.32% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 108.72M | 124.59M | 200.27M | 234.65M | 98.18M | 14.14M | 136.18K | 240.61K | 133.04K | 236.99K | 53.70K | 28.22K | 41.69K | 41.73K | 11.11K | 8.91K | 9.37K | 19.11K | 45.59K | 0.00 | 0.00 |
Selling & Marketing | 3.21M | 1.11M | 10.64M | 27.55M | 7.01M | 323.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 111.93M | 125.70M | 210.92M | 262.20M | 105.20M | 14.46M | 136.18K | 240.61K | 133.04K | 236.99K | 53.70K | 28.22K | 41.69K | 41.73K | 11.11K | 8.91K | 9.37K | 19.11K | 45.59K | 74.82K | 171.76K |
Other Expenses | 19.10M | 30.89M | 39.95M | 20.98M | 5.26M | 1.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 216.33K | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 131.03M | 156.59M | 250.87M | 283.17M | 110.45M | 15.66M | 136.18K | 240.61K | 133.04K | 236.99K | 53.70K | 28.22K | 41.69K | 41.73K | 11.11K | 8.91K | 9.37K | 19.11K | 45.59K | 74.82K | 179.99K |
Cost & Expenses | 202.11M | 234.37M | 349.86M | 352.26M | 136.39M | 17.46M | 144.07K | 248.26K | 140.99K | 244.77K | 62.73K | 38.92K | 51.02K | 52.05K | 20.47K | 19.73K | 17.56K | 26.90K | 64.89K | 74.82K | 575.01K |
Interest Income | 91.59K | 649.23K | 766.04K | 701.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 43.07M | 61.37M | 49.49M | 22.82M | 16.11M | 512.44K | 135.37 | 6.53K | 2.46K | 30.07K | 35.41K | 34.97K | 35.93K | 30.44K | 37.00K | 31.38K | 29.77K | 17.16K | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 25.74M | 34.46M | 43.71M | 23.54M | 5.15M | 1.57M | 22.82K | 6.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 216.33K | 0.00 | 10.08K | 0.00 | 0.00 |
EBITDA | -35.56M | -54.84M | -149.04M | -198.75M | -91.45M | -13.22M | -124.01K | -221.61K | -120.35K | -219.85K | -43.07K | -11.26K | -32.88K | -18.45K | 15.95K | 2.45K | 219.04K | -7.55K | -24.71K | -74.82K | -269.55K |
EBITDA Ratio | -25.26% | -37.81% | -94.86% | -152.93% | -229.87% | -494.85% | -618.00% | -831.49% | -582.98% | -882.08% | -219.12% | -40.73% | -181.26% | -54.90% | 43.80% | 11.04% | 1,080.18% | -39.05% | -82.07% | 0.00% | -88.24% |
Operating Income | -61.30M | -89.30M | -192.75M | -222.30M | -96.60M | -14.79M | -124.01K | -228.14K | -120.35K | -219.85K | -43.07K | -11.26K | -32.88K | -18.45K | 15.95K | 2.45K | 2.72K | -7.55K | -34.79K | -74.82K | -269.55K |
Operating Income Ratio | -43.53% | -61.56% | -122.68% | -171.05% | -242.83% | -553.54% | -618.00% | -855.98% | -582.98% | -882.08% | -219.12% | -40.73% | -181.26% | -54.90% | 43.80% | 11.04% | 13.40% | -39.05% | -115.55% | 0.00% | -88.24% |
Total Other Income/Expenses | -114.15M | -67.40M | -328.92M | -22.30M | -11.01M | -2.91M | -18.81 | 0.00 | -2.46K | -30.07K | -35.41K | -34.97K | -35.93K | -30.44K | -37.00K | -31.38K | 186.55K | -17.16K | 360.22K | 0.00 | -1.00M |
Income Before Tax | -175.45M | -143.61M | -515.35M | -263.23M | -110.73M | -15.38M | -124.14K | -228.14K | -122.80K | -249.92K | -78.48K | -46.23K | -68.81K | -48.88K | -21.05K | -28.93K | 189.27K | -24.72K | 325.43K | 0.00 | -1.27M |
Income Before Tax Ratio | -124.60% | -99.00% | -328.01% | -202.54% | -278.32% | -575.46% | -618.67% | -855.98% | -594.87% | -1,002.74% | -399.26% | -167.16% | -379.31% | -145.49% | -57.81% | -130.46% | 933.37% | -127.80% | 1,080.98% | 0.00% | -416.30% |
Income Tax Expense | -9.90M | 1.83M | -39.60M | 13.81M | 1.54M | 43.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.77K | 0.00 | 0.00 | 75.18K | 0.00 |
Net Income | -165.55M | -145.45M | -475.75M | -277.05M | -112.26M | -15.42M | -124.14K | -228.14K | -122.80K | -249.92K | -78.48K | -46.23K | -68.81K | -48.88K | -21.05K | -28.93K | 189.27K | -24.72K | 325.43K | -75.18K | -1.27M |
Net Income Ratio | -117.57% | -100.26% | -302.81% | -213.17% | -282.19% | -577.07% | -618.67% | -855.98% | -594.87% | -1,002.74% | -399.26% | -167.16% | -379.31% | -145.49% | -57.81% | -130.46% | 933.37% | -127.80% | 1,080.98% | 0.00% | -416.30% |
EPS | -0.14 | -0.27 | -1.76 | -2.62 | -2.77 | -26.33 | -0.21 | -0.56 | -0.50 | -0.93 | -1.76 | -1.03 | -1.54 | -1.09 | -0.47 | -0.65 | 4.24 | -0.55 | 7.28 | -1.68 | -28.73 |
EPS Diluted | -0.14 | -0.27 | -1.76 | -2.62 | -2.77 | -26.33 | -0.21 | -0.56 | -0.50 | -0.93 | -1.76 | -1.03 | -1.54 | -1.09 | -0.47 | -0.65 | 4.24 | -0.55 | 7.28 | -1.68 | -28.73 |
Weighted Avg Shares Out | 1.15B | 530.98M | 270.42M | 105.92M | 40.48M | 585.58K | 585.58K | 410.57K | 245.24K | 268.30K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.26K |
Weighted Avg Shares Out (Dil) | 1.15B | 530.98M | 270.42M | 105.92M | 40.48M | 585.58K | 585.58K | 410.57K | 245.24K | 268.30K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.26K |
MedMen Refuses To Close $73M Transaction With Ascend Wellness On Heels Of Regulatory Approval
Best Stocks for 2022: Deep Value Tech Stock POSaBIT Is A Can't Miss Cannabis Play
Ascend Wellness Gets Green Light From New York State To Invest $73M In MedMen's Subsidiary
MedMen Opens New Store In Boston's Fenway Park On Heels Of Litigation Hurdles & Management Shakeups
MedMen Opens First Store Since Management Shakeup: Boston's Fenway Park Gets New Cannabis Dispensary
MedMen To Carry Iconic LA Cannabis Brand Jungle Boys
MedMen Launches Medical Cannabis Delivery Across Florida
MedMen's Charitable Cannabis Holiday Shopping Gets Underway Soon In Six States
Cannabis Stocks Are A Coiled Spring - Brady Cobb's Industry Update (Podcast Transcript)
MedMen Bolsters Product Offering By Bringing Coveted Brands To Shelves Just In Time For Holidays
Source: https://incomestatements.info
Category: Stock Reports